I-Corps: Low-cost, handheld, manual cataract surgery device

I-Corps:低成本手持式手动白内障手术设备

基本信息

  • 批准号:
    2106140
  • 负责人:
  • 金额:
    $ 5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
    Standard Grant
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-15 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

The broader impact/commercial potential of this I-Corps project lies in its potential to address the leading cause of avoidable blindness. A total of 253 million people suffer from blindness or visual impairment, and 89% live in low- and middle-income countries (LMICs). Cataract surgery has been shown to improve physical and mental health, income, productivity, and quality of life, but it remains the leading cause of blindness globally. The limitations of phacoemulsification have prevented broad implementation across emerging markets, causing disadvantaged patients and those with mature cataracts to receive manual small incision cataract surgery (MSICS). MSICS involves removal of the whole, intact cataract through a large incision. This 6-7 mm incision leads to increased recovery time and astigmatism. Issues with affordability and acceptability of treatment delays care-seeking behavior, causing development of mature cataracts, and sometimes leading to blindness and significant functional limitations. By enabling non-ultrasonic fragmentation of even mature cataracts through a 3 mm incision in a time- and cost-efficient manner, the proposed technology has the potential to improve the acceptability and accessibility of cataract surgery in LMICs, increase the surgical volume and capacity of eye care systems, and provide improved visual and financial outcomes for the 21 million patients receiving cataract surgery annually in LMICs.This I-Corps project represents a novel approach to address vision loss and blindness due to cataracts. Globally, 12.6 million people are blind and 52.6 million have moderate-to-severe visual impairment due to cataracts. Cataract surgery is a simple, sight-restoring procedure where the clouded lens of the eye is removed and replaced with a synthetic lens. Cataract-related visual impairment is concentrated in low-and middle-income countries (LMICs), and is expected to grow dramatically with the aging population. The current phacoemulsification procedure involving ultrasonic cataract emulsification through a 3 mm incision is not ideal for emerging markets due to the length, cost, significant capital expense, recurring costs, and maintenance. Moreover, phacoemulsification is not optimal for treating ultra-hard, late-stage cataracts found in LMICs which require increased ultrasound power. The proposed technology consists of a low-cost, handheld, manual cataract surgery device which addresses the limitations of phacoemulsification and has the potential to achieve comparable or improved safety and efficacy. The device is deployed through a 3 mm incision and can capture and safely fragment all cataract sizes and hardnesses. It eliminates the need for capital equipment, maintenance, and electricity. Importantly, the device fits into the existing training and surgical workflow in emerging markets.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
I-Corps项目更广泛的影响/商业潜力在于它有可能解决可避免失明的主要原因。共有2.53亿人患有失明或视力障碍,其中89%生活在低收入和中等收入国家。白内障手术已被证明可以改善身心健康、收入、生产力和生活质量,但它仍然是全球失明的主要原因。超声乳化术的局限性阻碍了其在新兴市场的广泛应用,导致弱势患者和成熟白内障患者接受人工小切口白内障手术(msic)。mscs包括通过大切口切除整个完整的白内障。这个6-7毫米的切口会增加恢复时间和散光。治疗的可负担性和可接受性问题会延迟求医行为,导致成熟白内障的发展,有时还会导致失明和严重的功能限制。通过时间和成本效益的方式,通过3毫米切口实现成熟白内障的非超声碎裂,所提出的技术有可能提高中低收入国家白内障手术的可接受性和可及性,增加眼科保健系统的手术量和容量,并为中低收入国家每年接受白内障手术的2100万患者提供改善的视力和经济结果。这个I-Corps项目代表了一种解决白内障导致的视力丧失和失明的新方法。在全球范围内,有1260万人失明,5260万人因白内障而患有中度至重度视力障碍。白内障手术是一种简单的恢复视力的手术,将浑浊的晶状体取出并用人工晶状体代替。白内障相关的视力损害主要集中在低收入和中等收入国家(LMICs),并将随着人口老龄化而急剧增长。目前的超声乳化手术包括通过3mm切口进行超声白内障乳化手术,由于手术时间长、费用高、资本支出大、重复费用和维护等原因,在新兴市场并不理想。此外,超声乳化术并不是治疗中低收入患者超硬、晚期白内障的最佳选择,因为这些患者需要更高的超声功率。提出的技术包括低成本、手持式、手动白内障手术装置,解决了超声乳化的局限性,并有可能达到相当或更高的安全性和有效性。该设备通过一个3毫米的切口部署,可以捕获和安全地分割所有白内障大小和硬度。它消除了对资本设备、维护和电力的需求。重要的是,该设备适合新兴市场现有的培训和手术工作流程。该奖项反映了美国国家科学基金会的法定使命,并通过使用基金会的知识价值和更广泛的影响审查标准进行评估,被认为值得支持。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kunal Parikh其他文献

Kunal Parikh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

MSCEN聚集体抑制CD127low单核细胞铜死亡治疗SLE 的机制研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
新型PDL1+CXCR2low中性粒细胞在脉络膜新生血管中的作用及机制研究
  • 批准号:
    82271095
  • 批准年份:
    2022
  • 资助金额:
    56 万元
  • 项目类别:
    面上项目
CD9+CD55low脂肪前体细胞介导高脂诱导脂肪组织炎症和2型糖尿病的作用和机制研究
  • 批准号:
    82270883
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
CD21low/-CD23-B细胞亚群在间质干细胞治疗慢性移植物抗宿主病中的作用机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
探究Msi1+Lgr5neg/low肠道干细胞抵抗辐射并驱动肠上皮再生的新机制
  • 批准号:
    82270588
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
m6A去甲基化酶FTO通过稳定BRD9介导表观重塑在HIF2α(low/-)肾透明细胞癌中的作用机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    54.7 万元
  • 项目类别:
    面上项目
circEFEMP1招募PRC2促进HOXA6启动子组蛋白甲基化修饰调控Claudin4-Low型TNBC迁移侵袭和转移的作用机制
  • 批准号:
    82002807
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
上皮间质转化在Numb-/low前列腺癌细胞雄激素非依赖性中的作用及机制
  • 批准号:
    82003061
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
Bach2调控CD45RA-Foxp3low T细胞影响B细胞功能及其在系统性红斑狼疮中作用的机制研究
  • 批准号:
    81873863
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目

相似海外基金

I-Corps: Low-cost biochemical sensors to optimize agricultural inputs
I-Corps:用于优化农业投入的低成本生化传感器
  • 批准号:
    2311400
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
I-Corps: A Lightweight, Low-Cost, Liquid-Metal Cooling Vest for Prolonged Cooling
I-Corps:一款轻质、低成本的液态金属冷却背心,可实现长时间冷却
  • 批准号:
    2246456
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
I-Corps: A Low-cost and Non-contact Respiration Monitoring Method for COVID-19 Screening and Prognosis
I-Corps:一种用于 COVID-19 筛查和预后的低成本、非接触式呼吸监测方法
  • 批准号:
    2336852
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
I-Corps: Commercialization of a real-time, palm-size, low-cost, and wireless SARS-COV-II detector
I-Corps:实时、手掌大小、低成本、无线 SARS-COV-II 探测器的商业化
  • 批准号:
    2230853
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
I-Corps: Rapid, Low Cost Point-of-Care Microfluidic Cancer Screening Device
I-Corps:快速、低成本的护理点微流控癌症筛查设备
  • 批准号:
    2224974
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
I-Corps: Room Temperature Titanium Extraction from Low-Cost Pigments
I-Corps:从低成本颜料中室温提取钛
  • 批准号:
    2121590
  • 财政年份:
    2021
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
I-Corps: A Low-Cost Structured Light Monitoring System for Additive Manufacturing Processes
I-Corps:用于增材制造工艺的低成本结构光监控系统
  • 批准号:
    2112885
  • 财政年份:
    2021
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
I-Corps: Ultra-Low-Cost Mechanical Ventilator for COVID-19 and Other Respiratory Applications
I-Corps:用于 COVID-19 和其他呼吸应用的超低成本机械呼吸机
  • 批准号:
    2123506
  • 财政年份:
    2021
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
I-Corps: Low-Cost Holographic TelePresence System
I-Corps:低成本全息网真系统
  • 批准号:
    2049875
  • 财政年份:
    2021
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
I-Corps: Low-Cost Holographic TelePresence System
I-Corps:低成本全息网真系统
  • 批准号:
    2153693
  • 财政年份:
    2021
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了